Abstract:The Kirsten rat sarcoma viral (KRAS) oncogene is the most frequently mutated isoform of RAS, associated with 85 % of RAS-driven cancers. KRAS functions as a signaling hub, participating in various cellular signaling pathways and regulating a wide range of important activities, including cell proliferation, differentiation, growth, metabolism, and migration. Despite being the most frequently altered oncogenic protein in solid tumors, over the past four decades, KRAS has historically been considered "undruggable" owing to a lack of pharmacologically targetable pockets within the mutant isoforms. However, improvements in drug design and development have culminated in the development of selective inhibitors for KRAS mutants. Recent developments have led to the successful targeting of the KRASG12C mutant through covalent inhibitors that exploit the unique cysteine residue introduced by the mutation at 12th position. These inhibitors bind covalently to C12, locking KRAS in its inactive GDP-bound state and preventing downstream signaling. Some of these inhibitors have shown encouraging results in KRASG12C mutant cancer patients but suffer from drug resistance, toxicity, and low therapeutic efficacy. Recently, there have been great advancements in the discovery of drugs that directly target the switch I (S-I), switch-II (S-II) and S-I/II interface sites of KRAS mutant proteins. These include KRASG12C inhibitors like AMG510 (Sotorasib) and MRTX849 (Adagrasib), which have got FDA approval for non-small cell lung cancer harboring the KRASG12C mutation. There is no approved drug for cancers harboring other KRAS mutations, although efforts have expanded to target other KRAS mutations and the Switch I/II interface, aiming to disrupt KRAS-driven oncogenic signaling. Structure-activity relationship (SAR) studies have been instrumental in optimizing the binding affinity, selectivity, and pharmacokinetic properties of these inhibitors, leading to the development of promising therapeutic agents like Sotorasib and Adagrasib. This review provides an overview of the KRAS pathway, KRAS binding sites, strategies for direct and indirect inhibition using small molecules, and SAR based on the co-crystal structures of inhibitors with KRAS mutants which is expected to offer new hope for patients with KRAS-driven cancers through the development of new KRAS-targeted drugs.

Drugging the undruggable RAS: Mission Possible?

RAS-targeted therapies: is the undruggable drugged?

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

One Step Closer to Targeting RAS.

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

Combinatorial strategies to target RAS-driven cancers

Targeting KRAS in cancer

The current state of the art and future trends in RAS-targeted cancer therapies

An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Eliminating oncogenic RAS: back to the future at the drawing board

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C

Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling

Small molecule inhibitors of RAS proteins with oncogenic mutations

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers

Drugging the Next Undruggable KRAS Allele-Gly12Asp

Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?